Please try another search
For the three months ended 31 March 2022, AptaBio Therapeutics Inc revenues decreased 91% to W10.1M. Net loss decreased 18% to W2.6B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects R & D Expense decrease of 52% to W907.5M (expense), Interest Income increase of 25% to W383.3M (income), Commission Paid decrease of 11% to W123.8M (expense).
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 637.23 | 289.21 | 8.39 | 26.27 |
Gross Profit | 71.44 | 39.72 | 8.39 | 12.96 |
Operating Income | -6093.69 | -4213.64 | -6596.2 | |
Net Income | -3966.73 | -1271.72 | -4169.46 | -6620.46 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 89883.37 | 92519.12 | 100944.95 | |
Total Liabilities | 32368.33 | 31155.72 | 36889.11 | |
Total Equity | 57515.04 | 61363.39 | 64055.84 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -2459.45 | -7958.34 | ||
Cash From Investing Activities | 3543.72 | -599.79 | ||
Cash From Financing Activities | -35.02 | -35.11 | ||
Net Change in Cash | 1063.67 | -8606.43 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review